Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Ratios

LENZ Therapeutics (LENZ) Preferred Shares Issued (2023 - 2024)

LENZ Therapeutics (LENZ) has disclosed Preferred Shares Issued for 2 consecutive years, with -$83.0 million as the latest value for Q4 2024.

Quarterly Preferred Shares Issued changed N/A to -$83.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$66.0 million through Dec 2024, changed N/A year-over-year, with the annual reading at $83.0 million for FY2023, N/A changed from the prior year.
Preferred Shares Issued for Q4 2024 was -$83.0 million at LENZ Therapeutics, down from $17.0 million in the prior quarter.
The five-year high for Preferred Shares Issued was $66.0 million in Q1 2023, with the low at -$83.0 million in Q4 2024.